JP2024505093A5 - - Google Patents
Info
- Publication number
- JP2024505093A5 JP2024505093A5 JP2023546275A JP2023546275A JP2024505093A5 JP 2024505093 A5 JP2024505093 A5 JP 2024505093A5 JP 2023546275 A JP2023546275 A JP 2023546275A JP 2023546275 A JP2023546275 A JP 2023546275A JP 2024505093 A5 JP2024505093 A5 JP 2024505093A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- antigen receptor
- chimeric antigen
- intracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144337P | 2021-02-01 | 2021-02-01 | |
| US63/144,337 | 2021-02-01 | ||
| PCT/US2022/014792 WO2022165440A2 (en) | 2021-02-01 | 2022-02-01 | Treatment of neuroendocrine cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505093A JP2024505093A (ja) | 2024-02-02 |
| JP2024505093A5 true JP2024505093A5 (https=) | 2025-02-07 |
Family
ID=82653957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546275A Pending JP2024505093A (ja) | 2021-02-01 | 2022-02-01 | 神経内分泌がんの治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240415883A1 (https=) |
| EP (1) | EP4284432A4 (https=) |
| JP (1) | JP2024505093A (https=) |
| CN (1) | CN116940378A (https=) |
| AU (1) | AU2022212307A1 (https=) |
| CA (1) | CA3210515A1 (https=) |
| WO (1) | WO2022165440A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016016344A1 (en) * | 2014-07-29 | 2016-02-04 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| US10544201B2 (en) * | 2014-07-31 | 2020-01-28 | Cellectis | ROR1 specific multi-chain chimeric antigen receptor |
| AU2016334893B2 (en) * | 2015-10-08 | 2022-11-17 | Veracyte, Inc. | Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancer |
| TWI841554B (zh) * | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| SG11202107976SA (en) * | 2019-01-29 | 2021-08-30 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| AU2020248448B2 (en) * | 2019-03-26 | 2026-01-29 | The Regents Of The University Of California | Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers |
-
2022
- 2022-02-01 JP JP2023546275A patent/JP2024505093A/ja active Pending
- 2022-02-01 EP EP22746887.3A patent/EP4284432A4/en active Pending
- 2022-02-01 CN CN202280017666.0A patent/CN116940378A/zh active Pending
- 2022-02-01 AU AU2022212307A patent/AU2022212307A1/en active Pending
- 2022-02-01 US US18/274,145 patent/US20240415883A1/en active Pending
- 2022-02-01 CA CA3210515A patent/CA3210515A1/en active Pending
- 2022-02-01 WO PCT/US2022/014792 patent/WO2022165440A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102898514B1 (ko) | 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도 | |
| JP7490915B2 (ja) | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 | |
| US12059436B2 (en) | BCMA-CAR-T cells | |
| CN112638947B (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| Gacerez et al. | How chimeric antigen receptor design affects adoptive T cell therapy | |
| CN110615843B (zh) | 一种包含第三信号受体的嵌合抗原受体及其应用 | |
| US20190048085A1 (en) | Modified cells for immunotherapy | |
| EP3169703B1 (en) | Chimeric antigen receptor and its use | |
| WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
| JP2022535429A (ja) | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ | |
| JP2023534808A5 (https=) | ||
| IL279100B1 (en) | Diverse antigen binding sites, new platforms and other improvements for cell therapy | |
| JP2021536265A5 (https=) | ||
| JP2021534740A5 (https=) | ||
| US11725053B2 (en) | Chimeric antigen receptors comprising a human transferrin epitope sequence | |
| WO2017176525A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| WO2016030414A1 (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP2022527081A5 (https=) | ||
| EP3029137B1 (en) | Genetic modified pluri- or multipotent stem cells and uses thereof | |
| JP2025081512A5 (https=) | ||
| JP2022513372A5 (https=) | ||
| JP2024536859A5 (https=) | ||
| JP2024504162A5 (https=) | ||
| WO2023044991A1 (zh) | 一种特异性靶向肿瘤EpCAM抗原的抗体及应用 | |
| JP2024505093A5 (https=) |